News

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS)

that Demonstrate Elacestrant’s PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting

Contenuto disponibile solo in lingua inglese